Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Interventions to Delay RA Onset

Ruth Jessen Hickman, MD  |  October 9, 2024

Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:preventionRA Resource Center

Case Report: Voriconazole-Induced Periostitis

Amanda Moyer, MD, & Tamiko Katsumoto, MD  |  October 8, 2024

In this case report, a patient with voriconazole-induced periostitis exhibits classic symptoms & elevated ALP levels, which quickly resolve following the discontinuation of voriconazole.

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone paincase reportskeletal fluorosisvoriconazolevoriconazole-induced periostitis

Editor's Pick

A Practical Guide to Autoantibody Testing in Rheumatic Diseases

Donald Thomas, MD, FACP, FACR, RhMSUS, & Jason Liebowitz, MD  |  October 7, 2024

“ANA’s are some of most commonly ordered tests but what exactly are they and what do you do with a positive ANA? Check out the Editor’s Pick for October to learn more,” says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS.

Filed under:Conditions Tagged with:ANA testautoantibodiesautoantibody testingEditor's Picklaboratory tests

Bringing Lupus into the Light

Keri Losavio  |  October 7, 2024

With more than 350 research abstracts on systemic lupus erythematosus, lupus nephritis and related conditions accepted for presentation at ACR Convergence 2024, we’re happy to announce that Graciela S. Alarcón, MD, MPH, has accepted the monumental task of reviewing the abstracts and identifying those most likely to make a difference to clinical practice or lead…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2024ACR Convergence 2024 SLE

Ethics Forum: The ACR Code in Practice

Prajakta Masurkar, PhD, MPharm, & Charis Meng, MD  |  September 9, 2024

Ethical conduct is the cornerstone of any professional organization, particularly when its decisions have an impact on public health. The ACR recognizes the importance of upholding ethical standards and has established a Code of Ethics to guide its members. Here we explore the practical application of the ACR’s Code of Ethics.1 Manage Potential Conflicts Central…

Filed under:EthicsGuidancePractice Support Tagged with:ACR Code of EthicsEthics Forum

What’s New in Polymyalgia Rheumatica?

Jason Liebowitz, MD, FACR  |  July 31, 2024

Should all patients with polymyalgia rheumatica (PMR) have a vascular ultrasound assessment? What treatments are the safest and most efficacious for patients with PMR? Frank Buttgereit, MD, answered these questions and highlighted the latest research on PMR in this session at EULAR 2024.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPain Syndromes Tagged with:EULAR 2024GCAgiant cell arteritis (GCA)PMRPolymyalgia Rheumatica

Coagulation Education: Treatment Options for Antiphospholipid Syndrome

Jason Liebowitz, MD, FACR  |  July 31, 2024

Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsVasculitis Tagged with:Antiphospholipid syndromeAPScardiovascularEULAR 2024obstetric APSpregnancypregnancy complicationsthrombotic APS

What’s New in Treatment: IgA Vasculitis & IgA Nephropathy

Samantha C. Shapiro, MD  |  July 29, 2024

Dr. Jens Thiel provided a detailed overview of specific treatments for patients with immunoglobulin A (IgA) vasculitis and IgA nephropathy, highlighting treatments in early clinical trials.

Filed under:ConditionsEULAR/OtherMeeting ReportsVasculitis Tagged with:EULAR 2024IgA nephropathyIgA vasculitis

CAR-T Cells: Are We Closer to Drug-Free Remission Than We Think?

Samantha C. Shapiro, MD  |  July 8, 2024

Most Sunday mornings, I make myself an exceptional cup of pour-over coffee and sit down on my deck with the latest issue of the New England Journal of Medicine. I check out the image of the week. I read the case report with pen in hand, racing to diagnose the patient before the authors spill…

Filed under:Drug UpdatesGuidanceResearch Rheum Tagged with:CAR-T cell therapyRemission

State Copay Accumulator Legislation: An Overview

Joseph Cantrell, JD  |  June 25, 2024

As uncertainty persists around federal policies regarding copay accumulator programs, a growing number of states are stepping in. A total of 21 states have banned the programs and others are increasing transparency requirements

Filed under:Uncategorized Tagged with:copay accumulatorsstate legislation

  • « Previous Page
  • 1
  • …
  • 66
  • 67
  • 68
  • 69
  • 70
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences